title: A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria.
authors: Genentech, Inc, South San Francisco, Calif. Electronic address: harris.jeffrey@gene.com.
authors: Jeffrey M
authors: JM
authors: Harris
authors: Genentech, Inc, South San Francisco, Calif.
authors: Christopher R
authors: CR
authors: Cabanski
authors: Genentech, Inc, South San Francisco, Calif.
authors: Heleen
authors: H
authors: Scheerens
authors: Genentech, Inc, South San Francisco, Calif.
authors: Divya
authors: D
authors: Samineni
authors: Genentech, Inc, South San Francisco, Calif.
authors: Mary S
authors: MS
authors: Bradley
authors: Genentech, Inc, South San Francisco, Calif.
authors: Colette
authors: C
authors: Cochran
authors: Department of Dermatology, University Medical Center Mainz, Mainz, Germany.
authors: Petra
authors: P
authors: Staubach
authors: Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité-Universitätsmedizin Berlin, Berlin, Germany.
authors: Martin
authors: M
authors: Metz
authors: Division of Clinical Immunology and Allergy, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
authors: Gordon
authors: G
authors: Sussman
authors: Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité-Universitätsmedizin Berlin, Berlin, Germany.
authors: Marcus
authors: M
authors: Maurer
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D004311:Double-Blind Method; D006801:Humans; D007073:Immunoglobulin E / Q000378:metabolism; D000069444:Omalizumab / Q000627:therapeutic use*; D014581:Urticaria / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D018926:Anti-Allergic Agents; D000069444:Omalizumab; D007073:Immunoglobulin E